Clinical trials: Major Depression Moderate
Hepatic Impairment
Pharmacokinetics of AGO178 in Participants With Liver Impairment
AGO178 was developed for the treatment of depression. A new formulation is being tested in the present study: a tablet to be placed and dissolved under the tongue (sublingual tablet).
- Trial name
- NCT01531309
- Testing
- AGO178
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder, Major Depressive Episode
MRS and Medication Response: A Pilot Study
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild
- Trial name
- NCT03254342
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Major Depressive Disorder (MDD)
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KH607 in 120 participants diagnosed with moderate or severe Major Depressive Disorder.
- Trial name
- NCT07101120
- Testing
- KH607 tablets
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Mild to Moderate Depression
Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.
The purpose of the study is to describe, over 6 weeks, the evolution of depressive symptoms in patients with mild to moderate major depression in a strategy with Phytostandard® Rhodiola-Saffron supplementation
- Trial name
- NCT02981225
- Testing
- Phytostandard® Rhodiola-Saffron
- Where
- France
- Volunteers
- 59 people
- Sponsor
- PiLeJe
Depression
A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression
- Trial name
- NCT07485595
- Testing
- JS1-1-01 low-dose group, JS1-1-01 high-dose group
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Major Depression Moderate, Major Depression Severe
EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07748091
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Infant, Newborn, Hypoxia, Brain
Preemie Hypothermia for Neonatal Encephalopathy
This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to…
- Conditions
- Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic
- Trial name
- NCT01793129
- Testing
- Hypothermia, Normothermic Control
- Where
- 18 sites in United States
- Volunteers
- 168 people
- Sponsor
- NICHD Neonatal Research Network
Depression
Brief Behavioral Activation Treatment for Depression With Inpatients
The purpose of the current study was to examine Brief Behavioral Activation Treatment for Depressions (BATD) effectiveness, credibility, and acceptability with moderate to severly depressed inpatients.
- Trial name
- NCT02712918
- Testing
- Brief Behavioral Activation Treatment for Depression, Standard Care
- Volunteers
- 23 people
- Sponsor
- Lovisenberg Diakonale Hospital
Major Depressive Disorder
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)
The overall objective of this trial is to demonstrate clinically relevant superior antidepressant efficacy of the fixed dose combination PNB01 (low dose pipamperone and citalopram) over reference antidepressant treatment with…
- Trial name
- NCT01312922
- Testing
- PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
- Where
- 31 sites in United States, Canada
- Volunteers
- 555 people
- Sponsor
- PharmaNeuroBoost N.V.
Depression, Anxiety
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug…
- Conditions
- Depression, Anxiety, Major Depressive Disorder
- Trial name
- NCT06820723
- Testing
- CYB003
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University
Mild-moderate Unipolar Depression; Persistent Negative Affect
Dismantling Mindfulness: Contributions of Attention vs. Acceptance
This study addresses NCCAM's request for research that investigates the neuropsychological mechanisms underlying mind-body therapies, and for precise criteria and better delineation of meditation practices.
- Trial name
- NCT01831362
- Testing
- Mindfulness-Based Cognitive Therapy, Focused Attention (FA), Open- Monitoring
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Brown University
Moderate Dementia, Severe Dementia
Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia?
Dementia is a term used to describe a collection of symptoms including memory loss, problems with reasoning and communication, and a reduction in a person's ability to carry out daily activities.
- Trial name
- NCT04347668
- Testing
- Virtual Reality, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Western University, Canada
Depression
Rapid Improvement of Depression of Fluoxetine Combined With ATP
The clinical study is a randomized (1:1:1), double-blind, placebo-controlled clinical study. Recruit patients with moderate to severe depression.
- Trial name
- NCT05431413
- Testing
- Experimental group: Fluoxetine and ATP, Control group: Fluoxetine and Phosphocreatine
- Where
- China
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Anxiety, Anxiety Disorders
A Feasibility Study of Nature-based Health Interventions for People With Mild to Moderate Anxiety, Depression and Stress
Background and aimThe increased burden on mental health both globally and nationally is a serious challenge that requires attention and action from healthcare professionals, politicians, and decision-makers.
- Conditions
- Anxiety, Anxiety Disorders, Depression - Major Depressive Disorder, Depressive Disorder
- Trial name
- NCT06981000
- Testing
- Locally adapted nature-based health intervention
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- University of Copenhagen
Severe Asthma, Moderate or Severe Major Depressive Disorder
Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD).
- Trial name
- NCT00621946
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
Severe Depression, Moderate Depression
Nebulized Ketamine for the Treatment of Major Depressive Disorder
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
- Conditions
- Severe Depression, Moderate Depression, Ketamine, Midazolam
- Trial name
- NCT06752759
- Testing
- nebulized ketamine, nebulized midazolam
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Theresa Jacob, PhD, MPH
Major Depressive Disorder
Efficacy of Cognitive Behavioral to Hypnotherapeutic Treatment of Depression
The purpose of the study is to compare the efficacy of an Hypnotherapeutic Treatment of Depression to Cognitive Behavioral Treatment of Depression in patients with mild to moderate Major Depressive Episodes.
- Trial name
- NCT02375308
- Testing
- HDT, ACDT
- Where
- Germany
- Volunteers
- 153 people
- Sponsor
- University Hospital Tuebingen
Depression
Improvement of Depression With Use of ATP
This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the…
- Trial name
- NCT06266715
- Testing
- ATP Group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Major Depressive Disorder
The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder
Study Type: Interventional Study Design: Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)…
- Trial name
- NCT02657980
- Testing
- Yband(YDT-201N)
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Ybrain Inc.
Depressive Disorder, Depression
The Role of Inflammatory Processes in Development and Treatment of Depression
The study investigates the influence of inflammatory processes on the development and the course of uni- and bipolar depression.
- Conditions
- Depressive Disorder, Depression, Inflammation
- Trial name
- INFLAME-D (NCT03920475)
- Testing
- Sertraline or venlafaxine, Immune parameters
- Volunteers
- 104 people
- Sponsor
- Kliniken Essen-Mitte